MaaT Pharma S.A.
MAAT.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €3 | €2 | €1 | €1 |
| % Growth | 44.3% | 55.8% | 47.1% | – |
| Cost of Goods Sold | €1 | €1 | €0 | €0 |
| Gross Profit | €2 | €1 | €1 | €1 |
| % Margin | 61.1% | 35.2% | 76.3% | 82.9% |
| R&D Expenses | €27 | €20 | €14 | €9 |
| G&A Expenses | €3 | €2 | €1 | €1 |
| SG&A Expenses | €4 | €5 | €2 | €1 |
| Sales & Mktg Exp. | €1 | €1 | €1 | €0 |
| Other Operating Expenses | -€1 | €0 | -€2 | -€1 |
| Operating Expenses | €30 | €25 | €15 | €10 |
| Operating Income | -€28 | -€20 | -€14 | -€9 |
| % Margin | -884% | -895.1% | -948% | -914.9% |
| Other Income/Exp. Net | -€4 | €0 | -€0 | -€0 |
| Pre-Tax Income | -€32 | -€20 | -€14 | -€9 |
| Tax Expense | -€4 | €0 | €0 | €0 |
| Net Income | -€29 | -€20 | -€14 | -€9 |
| % Margin | -898.8% | -885% | -959% | -927.9% |
| EPS | -2.2 | -1.73 | -1.39 | -3.72 |
| % Growth | -27.2% | -24.5% | 62.6% | – |
| EPS Diluted | -2.2 | -1.73 | -1.39 | -3.72 |
| Weighted Avg Shares Out | 13 | 11 | 10 | 2 |
| Weighted Avg Shares Out Dil | 13 | 11 | 10 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €1 | €0 | €0 |
| Interest Expense | €1 | €0 | €0 | €0 |
| Depreciation & Amortization | €2 | €1 | €0 | €0 |
| EBITDA | -€26 | -€22 | -€13 | -€9 |
| % Margin | -819.2% | -990.4% | -916% | -881.7% |